Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$48.15 USD
0.00 (0.00%)
Updated May 20, 2024 01:51 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BPMUF 48.15 0.00(0.00%)
Will BPMUF be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BPMUF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPMUF
Basilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep going
BPMUF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?
Here's What Could Help Basilea Pharmaceutica AG (BPMUF) Maintain Its Recent Price Strength
Other News for BPMUF
Basilea price target raised to CHF 94 from CHF 85 at H.C. Wainwright